Susan Haigney

Susan Haigney is lead editor of BioPharm International®.

Articles by Susan Haigney

Pharmaceutical Technology® spoke with Peter Freed, head of Global Pharma CTS, Roquette, about a variety of materials-related topics including protein stability, tablet coating, sustainability, and securing the supply chain.

Pharmaceutical Technology® spoke with Christian Dowdeswell, managing director, Arcinova, a Quotient Sciences Company, ahead of CPHI Frankfurt 2025 to find out what makes an end-to-end service provider beneficial to sponsor companies and how digital technologies are changing the industry.

Pharmaceutical Technology® spoke with Tara Dougal, Event Director for Pharma at Informa Markets about what attendees at CPHI Frankfurt should expect this year.

Targeted Alpha Therapy as a cancer treatment in clinical trials as a oncology therapies targeting malignant tumors with radioactive particles destroying cells | Image Credit: ©freshidea -stock.adobe.com

Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.

Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging, at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.

Pharmaceutical Technology® spoke with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, to learn more about Crown Bioscience’s collaboration with Medicines Discovery Catapult on a new development platform for radiopharmaceuticals.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates, and Siegfried Schmitt, PhD, Parexel, answer questions on the use of real-world evidence for both small-molecule and large-molecule drug development. In addition, they tackle a question on supply chain security problems that arise during transportation of pharmaceutical goods.

Nitrosamines. Doctor in smock points with his finger to a search box. The term Nitrosamines is in focus. Symbol for illness, health, medicine | Image Credit: © MQ-Illustrations -stock.adobe.com

Pharmaceutical Technology® spoke with Todd Sprouse, associate director, Analytical Services, and Erik Feldmann, PhD, principal technical advisor, Client Solutions & Proposals, both with Cambrex, to find out more about the challenging situation.

Susan J. Schniepp, Distinguished Fellow, Regulatory Compliance Associates, joins PDA CEO Glenn Wright and Melissa Seymour, Executive Vice President, Global Quality, Eli Lilly and Company, to talk about the regulatory and quality topics discussed at the 2025 PDA Regulatory Conference.

Latest Updated Articles